Prelims: Current events of national and international importance | Science & Technology
Why in news?
Bharat Biotech’s arms, Nucelion and VeGen Bio, a Hyderabad-based precision oncology company, to partner for CAR-T therapy.
- VL-2511 – A first-in-class dual-target autologous chimeric antigen (two cancer-related antigens) receptor (CAR)-T cell therapy that simultaneously targets BCMA and CD19 proteins.
CAR-T (Chimeric Antigen Receptor T-cell) Therapy – A personalised immunotherapy in which a patient's T-cells are genetically modified to recognise and destroy cancer cells.
- Collaboration – Nucelion Therapeutics (a wholly owned subsidiary of Bharat Biotech) and VeGen Bio have announced a strategic partnership to develop and manufacture India’s first dual BCMA/CD19 autologous CAR-T cell therapy, VL-2511, targeting multiple myeloma.
- Collaboration’s Objective – To process optimisation, manufacturing yields, and operational efficiency to improve production economics, aiming to reduce manufacturing costs and improve access to advanced cell therapies in India.
- Manufacturing Facility – Production and technology transfer will take place at Nucelion’s single-site GMP manufacturing facility in Hyderabad, designed to meet CDSCO, US FDA, and EMA regulatory standards.
- Role of the partners – VeGen Bio provides the therapeutic candidate and oncology expertise.
- Nucelion will handle technology transfer, clinical-stage manufacturing, and commercial-scale production at its GMP-certified Hyderabad facility.
- Clinical and Commercial Goals – The partnership will support Phase I and II clinical trials in India, with an overarching target for commercialisation by 2028.
References
- The Hindu | Bharat Biotech arm Nucelion, VeGen Bio to partner for CAR-T therapy
- Business Line | Nucelion & VeGen Bio to partner for CAR-T therapy
